, Taiwan
160 views

Taiwanese insurers ceases sales of COVID-19 insurance

Insurers blamed rising infections for halting sale of COVID-19 cover.

Taiwanese property and casualty insurers (P&C) have halted the sale of COVID-19 insurance policies amidst rising infections, according to the Financial Supervisory Commission.

As of last week, all local P&C insurance companies have stopped the sales of COVID-19 insurance policies that compensate people if they are quarantined, the FSC said.

Ten insurers have stopped selling such COVID-19 policies, including Chung Kuo Insurance Co, MSIG Mingtai Insurance Co, CTBC Insurance Co), and Tokio Marine Newa Insurance Corp.

The commission also reported that the number of policies that compensate policyholders dropped from only three to zero in one night, after Cathay Century Insurance and Union Insurance Co both announced that they would no longer be offering such products. Cathay Century announced on its website that it had decided to cease selling such products because of the rise in infections.

You may also like:

Tokio Marine launches own venture capital fund

Allianz Life reveals estate planning awareness in Malaysia on the rise

COMMENTARY: Moving towards a “higher bottom line” in the insurance sector in Southeast Asia

Follow the link s for more news on

Prudential, StanChart memperkuat 25 Tahun kemitraan bancassurance

Mereka memiliki kemitraan bancassurance terlama di Singapura dan Asia.

MSIG Asia dan RiskPoint mempertaruhkan asuransi energi terbarukan

Kawasan Asia-Pasifik berpotensi menarik investasi sebesar $3 triliun dalam pembangkitan listrik hingga 2033.

Kantor pusat Pru Life UK di Manila menerapkan kerja hibrida

Kantor ini memiliki area rekreasi dan kesehatan untuk membantu karyawan menyegarkan diri.

Etiqa meluncurkan produk asuransi takaful pertama di Singapura

Permintaan terhadap produk keuangan Islam dari Timur Tengah dan Asia Tenggara terus meningkat.

Perusahaan asuransi jiwa Singapura bidik pertumbuhan di 2025

Dorongan untuk solusi layanan kesehatan inovatif di tengah inflasi medis menjadi tantangan.